Avian influenza present on P.E.I., but not a risk to general public, experts say
The virus has been present on the Island for years, and was recently confirmed to have infected a large number of dying and dead Canada geese in Vernon Bridge, P.E.I.
"It serves as a reminder that the virus is out there and it is circling," said Dr. Jill Wood, P.E.I.'s chief veterinary officer.
The highly contagious virus can be transmitted to birds and mammals, including humans. But the risk to the general public is low, Wood said.
"That being said, we're certainly cautioning people not to approach sick wildlife or handle ill wildlife," she said.
If someone needed to interact with sick or dead wildlife — like to remove a dead crow from their lawn, for example — Wood offered some advice: "Wear a mask, wear gloves, double bag it."
She also added that it's best to use a shovel and not your hands.
How the virus is spread
The H5N1 virus is spread by contact with bodily fluids, including feces, said Marguerite Cameron, communicable disease epidemiologist at the Chief Public Health Office.
While human infection is rare, it can occur through close contact with infected birds or heavily infected environments such as poultry farms, Cameron said.
Using personal protective equipment — or PPE — is very important to reduce exposure, she said.
Cameron said her advice to Islanders is to always keep distance from wild birds and wild animals.
"Don't handle them, don't pick them up, don't feed them," she said.
'The virus is out there. It's something to be aware of but it's not something that should consume your life or make you anxious,' says Wade Sweet. (Taylor O'Brien/CBC)
Islanders should also keep pets away from any animals that might be sick, dying or dead, as mammals can become infected by scavenging on dead birds, Cameron said.
"That's why it's important for pet owners especially to make sure that their pets are not accessing any sick or dead animals," she said.
If there is a dead bird or animal that Islanders feel concerned about, they can call the Forests, Fish and Wildlife division of the province's Department of Environment, Water and Climate Change.
Staying safe and healthy
In February, the Public Health Agency of Canada said it purchased 500,000 doses of a human vaccine to protect those most at risk of exposure to the virus.
P.E.I. will have access to this stockpile, Cameron said, adding that there is an allocation framework and a risk assessment to determine eligibility.
Currently, the national advisory committee on immunization does not have recommendations as to how the vaccine will be deployed more broadly, she said.
What Islanders can do is ensure they are up to date with their seasonal flu vaccine, Cameron said.
"While [seasonal flu] vaccine won't protect them against avian influenza, it will protect them from potentially getting a co-infection with avian influenza and seasonal flu," she said, adding that a co-infection could result in more critical illness.
The two flu viruses could also exchange genetic material, which could potentially result in a new influenza strain, she said.
"That is what we're really trying to avoid," she said.
Cameron says her advice to Islanders is to always keep distance from wild birds and wild animals. (Taylor O'Brien/CBC)
For Dr. Wade Sweet, a veterinarian at West Prince Veterinary Hospital, an avian influenza vaccine is something he said he would be interested in getting if it was offered.
Until then, he relies on basic biosecurity measures such as wearing clean coveralls, boots and gloves when handling birds.
For Islanders wondering about food safety, Sweet said cooked poultry, eggs and pasteurized dairy products are still safe to consume.
"Anything you see that's in the grocery store, it's been pasteurized... it's not going to infect you," he said.
It's important for pet owners especially to make sure that their pets are not accessing any sick or dead animals - Marguerite Cameron
Sweet said the risk to the general public is low, and Islanders shouldn't be overly concerned.
"The virus is out there. It's something to be aware of but it's not something that should consume your life or make you anxious," he said.
"If the incidence of the virus increases, if we have more flocks that suddenly die, it'll be something to be more aware of. But for right now, it's something to know that it's there, but not be scared of."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
Toronto Public Health warns of possible Hepatitis A exposure at downtown restaurant
Toronto Public Health is warning customers who dined at a King Street W. restaurant that they may have been exposed to Hepatitis A. CBC'S Naama Weingarten has more details.
Yahoo
4 days ago
- Yahoo
Why Cathie Wood Is Loading Up on This Hot Growth Stock (And Should You?)
In a market dominated by headlines about artificial intelligence (AI), cloud computing, and digital platforms, it is easy to overlook some of the most transformative developments in the life sciences. Cathie Wood, CEO of ARK Invest and known for her bold bets on disruptive innovation, has her sights set on Illumina (ILMN), a company that connects science and technology. On July 22, Wood's ARK's Genomic Revolution ETF (ARKG) bought 31,265 shares of Illumina, amounting to nearly $2.98 million, bringing the total investment in the company to $32 million. It is the ETF's 15th largest holding, comprising 2.8% of the overall portfolio. More News from Barchart UnitedHealth Stock Spirals Lower Again. Don't Buy the Dip. This Self-Driving Car Stock Is Surging on a Major Nvidia Boost Auto Revenue Keeps Plunging at Tesla. Should You Buy the TSLA Stock Dip or Run Far Away? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Let's find out if investors should follow Wood's lead and buy Illumina stock here. A High-Conviction Bet on the Future of Medicine Valued at $16.6 billion, Illumina is a biotechnology company that specializes in genome sequencing, or the process of reading and analyzing DNA. It manufactures machines (sequencers), software, and chemical kits that are used to decode the genetic material (DNA) of humans, animals, plants, and bacteria. Illumina's technology is used in hospitals and clinics, by cancer researchers, pharmaceutical companies, agricultural scientists, academics, and research institutions, among others. Some of its products include the NovaSeq X Series, iScan System, iSeq 100 System, Illumina DNA Prep, Illumina Stranded mRNA Prep, and many others. Illumina's stock price has dropped significantly since its 2021 highs, falling from above $500 to around the $100-$120 range by mid-2025. Much of this decline can be attributed to a series of self-inflicted wounds, most notably its controversial acquisition of cancer detection company Grail. However, with the Grail divestment in 2024 and a new CEO, Jacob Thaysen, in charge, Illumina appears to be refocusing on its core business of making genome sequencing cheaper, faster, and more accessible. Why the Timing Matters Now Wood is known for buying when volatility is high, particularly when she believes the market has overcorrected due to near-term concerns. Following the Grail divestment, leadership change, and a multi-quarter slump in revenue growth, investor sentiment is bearish on Illumina stock, explaining the nearly 20% drop year-to-date. However, Wood saw this as an opportunity to stock up on this rising genomic star. Illumina's financial performance appears to be stabilizing. For a growth investor like Wood, who prefers to overlook short-term earnings volatility in favor of long-term potential, these improvements are a welcome sign that the company is on the right track. In the first quarter, while revenue growth dipped slightly by 1.4%, the company improved its margins and reduced unnecessary expenses. Illumina exceeded revenue expectations and reaffirmed full-year guidance. Adjusted gross margins increased to 67.4% as a result of improved manufacturing efficiency and lower R&D costs. Adjusted earnings per share fell to $0.97 from $0.98 in the prior year's quarter. Remaining performance obligations (RPO) totaled $891 million, of which Illumina expects to generate 83% in revenue over the next year. With a reasonable debt-equity ratio of 0.63x, Illumina's balance sheet is stable. The company also generated a positive free cash flow of $208 million during the quarter. Illumina will report its second-quarter earnings on July 31. Analysts expect revenue of $1.05 billion on earnings per share of $1.01. Analysts predict a 3% drop in revenue for the full year but earnings growth of 72.9% to $4.24 per share, with an additional 9.5% increase expected in 2026. Another factor that may have influenced ARK's decision to increase its stake in Illumina is valuation. The stock is currently trading at 22 times forward earnings for 2026 and three times forward sales. Illumina has the world's largest genomics dataset, giving the company a competitive advantage. Many of Illumina's future revenue streams, including large-scale population sequencing contracts and new clinical applications in oncology and rare diseases, are not fully priced into current projections. This reasonable valuation represents a buying opportunity for a growth stock with excellent long-term prospects. What Is Wall Street Saying About Illumina Stock? Overall, the consensus on Illumina stock is a 'Moderate Buy.' Of the 22 analysts covering the stock, nine recommend a 'Strong Buy,' one suggests a 'Moderate Buy,' nine rate it a 'Hold,' one says it is a 'Moderate Sell,' and two have given it a 'Strong Sell' rating. The stock is trading close to its average target price of $106.83. However, the high price estimate of $185 suggests a rally of over 76.8% from current levels. The Key Takeaway Wood's stake in Illumina is a calculated investment based on extensive research, long-term vision, and a firm belief in the power of genomics to transform healthcare. Now, with a lower cost structure, a clear path back to profit growth, and exciting new products on the market, Illumina is poised for a turnaround. For investors with patience and a long horizon, Illumina stock represents a one-of-a-kind opportunity to invest in genomic infrastructure. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
5 days ago
- Yahoo
Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study
Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administration Potential for single intranasal or intramuscular dose could differentiate Novavax's vaccine as part of pandemic emergency preparedness efforts GAITHERSBURG, Md., July 24, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza vaccine candidate, leveraging Novavax's recombinant, protein-based nanoparticle technology and Matrix-M® adjuvant, induced robust immune responses by either single or two-dose intranasal (IN) or intramuscular (IM) administration in nonhuman primates. Results were published in Nature Communications. "These preclinical results underscore the promise and potential of our pandemic influenza program as well as the strength of our technology platform and our ability to deliver against our corporate growth strategy," said Ruxandra Draghia-Akli, MD, PhD, Executive Vice President and Head of Research and Development, Novavax. "Our R&D pipeline focuses on delivering assets ready for partnership and prioritizing areas of unmet medical need, including vaccines for avian pandemic influenza, where we see clear potential advantages for our technology compared with other vaccines that are licensed or in development." Results showed that a single dose administered by either IN or IM routes induced neutralizing antibody responses (IN: 1:54; IM: 1:1,160), at or above the 1:40 titer generally considered to be a protective antibody response. The data showed even higher levels of immunity after two doses. These data suggest that even a single IN dose has the potential to provide protective immunity in individuals previously exposed to seasonal influenza either by vaccination or infection. Further, data showed Novavax's H5N1 vaccine candidate elicited broad antibody responses, suggesting the potential to protect against forward-drift variants from currently circulating strains of the H5N1 virus. H5N1, a highly pathogenic and dynamic avian pandemic influenza virus, is of concern due to its potential to mutate into a strain adapted for sustained human-to-human transmission. To date, there have been 70 confirmed total reported human cases in the U.S., and one death associated with H5N1 avian pandemic influenza infection.1 As of July 2025, no reported cases in the U.S. have been proven to result from human-to-human transmission. As part of its corporate growth strategy, Novavax is making targeted investments in early-stage development programs to create value. Novavax intends to pursue funding, partnership and licensing opportunities for its H5N1 vaccine candidate. About Novavax Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. The Company's growth strategy seeks to optimize its existing partnerships and expand access to its proven technology platform via research and development (R&D) innovation, organic portfolio expansion in infectious disease and beyond, and forging new partnerships and collaborations with other companies. Please visit and LinkedIn for more information. Forward-Looking Statements Statements herein relating to the future of Novavax, its operating plans and prospects, its partnerships, and the potential for a single intranasal or intramuscular dose differentiating Novavax's H5N1 vaccine, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges pursuing additional partnership opportunities; challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification, assay validation and stability testing, necessary to satisfy applicable regulatory authorities; challenges or delays in conducting clinical trials or studies for its product candidates; challenges or delays in obtaining regulatory authorization for its product candidates, including for future COVID-19 variant strain changes, its CIC vaccine candidate, its stand-alone influenza vaccine candidate or other product candidates; manufacturing, distribution or export delays or challenges; Novavax's substantial dependence on Serum Institute of India Pvt. Ltd. and Serum Life Sciences Limited for co-formulation and filling Novavax's COVID-19 vaccine and the impact of any delays or disruptions in their operations; difficulty obtaining scarce raw materials and supplies including for its proprietary adjuvant; resource constraints, including human capital and manufacturing capacity; constraints on Novavax's ability to pursue planned regulatory pathways, alone or with partners; challenges in implementing its global restructuring and cost reduction plan; challenges in obtaining commercial adoption and market acceptance of its updated COVID-19 vaccine or any COVID-19 variant strain containing formulation, or for its CIC vaccine candidate and stand-alone influenza vaccine candidate or other product candidates; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities, including requirements to deliver doses that may require Novavax to refund portions of upfront and other payments previously received or result in reduced future payments pursuant to such agreements and challenges in amending or terminating such agreements; challenges related to the seasonality of vaccinations against COVID-19; challenges related to the demand for vaccinations against COVID-19 or influenza; challenges in identifying and successfully pursuing innovation expansion opportunities; Novavax's expectations as to expenses and cash needs may prove not to be correct for reasons such as changes in plans or actual events being different than its assumptions; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at and for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Contacts: Investors Luis Sanay, CFA 240-268-2022 ir@ Media Giovanna Chandler (844) 264-8571 media@ References U.S. Centers for Disease Control and Prevention. H5 Bird Flu: Current Situation. 2025. Available at: View original content to download multimedia: SOURCE Novavax, Inc.